<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes - Tan, HJ - 2014 | Cochrane Library</title> <meta content="Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes - Tan, HJ - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006779.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes - Tan, HJ - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006779.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006779.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes" name="citation_title"/> <meta content="Hui Jeen Tan" name="citation_author"/> <meta content="Royal Manchester Children's Hospital" name="citation_author_institution"/> <meta content="huijeen.tan@gmail.com" name="citation_author_email"/> <meta content="Jaspal Singh" name="citation_author"/> <meta content="Birmingham Children's Hospital" name="citation_author_institution"/> <meta content="Rajat Gupta" name="citation_author"/> <meta content="Birmingham Children's Hospital" name="citation_author_institution"/> <meta content="Christian de Goede" name="citation_author"/> <meta content="Royal Preston Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD006779.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/09/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006779.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006779.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006779.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Watchful Waiting; Anticonvulsants [*therapeutic use]; Benzodiazepines [therapeutic use]; Carbamazepine [analogs &amp; derivatives, therapeutic use]; Clobazam; Epilepsy [*drug therapy, physiopathology]; Fructose [analogs &amp; derivatives, therapeutic use]; Induction Chemotherapy [methods]; Levetiracetam; Oxcarbazepine; Piracetam [analogs &amp; derivatives, therapeutic use]; Placebos; Randomized Controlled Trials as Topic; Thiazines [therapeutic use]; Topiramate" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006779.pub2&amp;doi=10.1002/14651858.CD006779.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="UiM8QuvV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006779\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006779\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006779\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006779\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006779.pub2",title:"Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes",firstPublishedDate:"Sep 5, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UiM8QuvV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006779.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006779.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006779.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006779.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006779.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006779.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006779.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006779.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006779.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006779.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2620 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006779.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full#CD006779-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full#CD006779-sec-0045"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full#CD006779-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full#CD006779-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full#CD006779-sec-0024"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full#CD006779-sec-0025"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full#CD006779-sec-0033"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full#CD006779-sec-0044"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/appendices#CD006779-sec-0050"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/table_n/CD006779StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/table_n/CD006779StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/information#CD006779-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Hui Jeen Tan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/information#CD006779-cr-0003">Jaspal Singh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/information#CD006779-cr-0004">Rajat Gupta</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006779.pub2/information#CD006779-cr-0005">Christian de Goede</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/information/en#CD006779-sec-0056">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 September 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006779.pub2">https://doi.org/10.1002/14651858.CD006779.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006779-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006779-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006779-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006779-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006779-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006779-abs-0001" lang="en"> <section id="CD006779-sec-0001"> <h3 class="title" id="CD006779-sec-0001">Background</h3> <p>Benign Epilepsy with Centro Temporal Spikes (BECTS) is a common epilepsy syndrome with onset in childhood which almost always remits by adolescence. It is characterised by focal seizures associated with motor signs and somatosensory symptoms, at times progressing to become generalised. The characteristic interictal EEG shows normal background activity with centrotemporal spikes which are more prominent in sleep. The prognosis is good though subtle cognitive impairment has been implicated. Antiepileptic drug (AED) treatment is used if seizures are frequent or occurring in the daytime. </p> </section> <section id="CD006779-sec-0002"> <h3 class="title" id="CD006779-sec-0002">Objectives</h3> <p>To evaluate whether or not treatment with AEDs changes the short‐ or long‐term outcome of children with BECTS or both. </p> </section> <section id="CD006779-sec-0003"> <h3 class="title" id="CD006779-sec-0003">Search methods</h3> <p>We searched the following databases: the Cochrane Epilepsy Group Specialized Register (30 April 2013), the Cochrane Central Register of Controlled Trials (CENTRAL, <i>The Cochrane Library</i> 2013, Issue 4: (April 2013)), MEDLINE (Ovid, 1946 to 30 April 2013), SCOPUS (30 April 2013), ClinicalTrials.gov (30 April 2013) and the WHO International Clinical Trials Registry Platform ICTRP (30 April 2013). We also handsearched the reference lists of articles that were considered for inclusion in the review. </p> </section> <section id="CD006779-sec-0004"> <h3 class="title" id="CD006779-sec-0004">Selection criteria</h3> <p>All randomised controlled trials (RCTs) that compared the use of different AEDs, or compared the use of AEDs with no treatment, or placebo in children with BECTS. </p> </section> <section id="CD006779-sec-0005"> <h3 class="title" id="CD006779-sec-0005">Data collection and analysis</h3> <p>Data were independently extracted by all four of the review authors and discrepancies were resolved by discussion. Analysis included assessment of risk of bias, quality of evidence of individual studies, heterogeneity, and statistical analysis of the effects on seizure remission and cognition. </p> </section> <section id="CD006779-sec-0006"> <h3 class="title" id="CD006779-sec-0006">Main results</h3> <p>There were six eligible studies but only four had sufficient data at the time of this review. The four RCTs included in this review reported on a total of 262 participants. One study, a placebo‐controlled trial with a low risk of bias, found that individuals on sulthiame were significantly more likely to remain in seizure remission during the three and six months from commencement of treatment than those on placebo (3 months: RR 2.26, 95% CI 1.48 to 3.44; 6 months: RR 2.63, 95% CI 1.43 to 4.86, 66 participants, moderate quality evidence). The other three trials, all open‐labelled studies, had a high risk of bias and did not show any significant differences in terms of seizure remission between AEDs. One compared levetiracetam with oxcarbazepine (3 months: RR 1.13, 95% CI of 0.93 ‐ 1.36; 12 months: RR of 1.29 with 95% CI of 0.89 ‐ 1.86, 39 participants, low to very low quality evidence), one clobazam with carbamazepine (4‐40 weeks: RR of 1.04, 95% CI of 0.67 ‐ 1.62; last 9 months: RR of 1.06 with 95% CI of 0.84, 1.34, 45 participants, low quality evidence), and one carbamazepine with topiramate (28 weeks: RR 1.02 with 95% CI of 0.8 ‐ 1.3, 112 participants, low quality evidence). </p> <p>Other outcome measures assessed included time to first seizure after randomisation which was only obtained in the sulthiame versus placebo study as a hazard ratio of 7.8 (95% CI 2.66 ‐ 22.87). There were no significant differences between the proportion of participants who had adverse events, apart from a higher incidence of rash in the carbamazepine group (14.8%) when compared with topiramate (1.7%), or the proportion who withdrew from treatment due to adverse events, when this was reported. Two trials (carbamazepine versus topiramate, and clobazam versus carbamazepine) evaluated the effects on cognition. The studies were of low to very low quality evidence showing no clear difference in cognition at the end of the study periods between the AEDs compared. A meta‐analysis was not performed as the RCTs evaluated different therapies. </p> </section> <section id="CD006779-sec-0007"> <h3 class="title" id="CD006779-sec-0007">Authors' conclusions</h3> <p>There is evidence from one trial reviewed that sulthiame is effective for seizure remission in the short term in children with BECTS although the precision of the effect estimate is uncertain due to its small sample size. There were no significant differences in the proportion of adverse events between treatment groups studied, including those resulting in withdrawal of treatment. There is insufficient evidence about the medium to longer term effects on seizure control, the optimum antiepileptic drug treatment and the effects of AED treatment on cognition. There is a need for more good quality randomised controlled trials to address these questions to aid the management of children with BECTS. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006779-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006779-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006779-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006779-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006779-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD006779-abs-0005">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006779-abs-0004" lang="en"> <h3>Antiepileptic drugs versus no treatment or placebo for children with benign epilepsy with centro temporal spikes </h3> <p>Benign epilepsy with centro temporal spikes is one of the most common childhood seizure disorders . Treatment for this disorder has been controversial as almost all individuals achieve seizure freedom by adolescence. However, this seizure disorder may not be as benign as the name suggests as children may have specific cognitive impairment. Treatment is started if seizures are felt to be frequent and intrusive. </p> <p>There were few studies found (searches conducted on 30th April 2013) with few antiepileptic drugs compared. One of the four studies included showed evidence that the antiepileptic drug, sulthiame, may have a positive effect in reducing seizure frequency in BECTS in the short term. There were no significant differences in the number of patients with adverse events apart from a higher risk of rash when carbamazepine was compared to topiramate. The number of patients who discontinued treatment as a result of adverse events was also not significant in the studies reviewed. There is insufficient evidence about whether or not treating with antiepileptic drugs has any effect on seizure freedom in the longer term or on a child’s cognition. The optimum treatment has yet to be identified. More research is needed to look into the effectiveness of treatment versus no treatment on seizure control and intellect, and compare the existing treatments. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006779-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006779-sec-0045"></div> <h3 class="title" id="CD006779-sec-0046">Implications for practice</h3> <section id="CD006779-sec-0046"> <p>Treatment with antiepileptic drugs can be effective in producing seizure remission in children with BECTS and there is some evidence for remission in the short term with sulthiame. There were no significant differences in adverse effects which resulted in discontinuation of treatment. Currently, there is insufficient evidence about the use of AEDs upon which to base practice. The decisions about when to treat and which antiepileptic drugs to use need careful consideration for each individual patient and an informed discussion with parents and care‐givers. Until further research is conducted, this decision should take into account the intrusiveness of seizures, whilst acknowledging the uncertainties of the effects of treatment on cognition. </p> </section> <h3 class="title" id="CD006779-sec-0047">Implications for research</h3> <section id="CD006779-sec-0047"> <p>There is a need for good quality randomised‐controlled trials to provide evidence for the optimum management of children with BECTS. Factors that reduced the quality of studies in this review included inadequate blinding of participants and/or personnel, inconsistencies in the reporting of results, large numbers of patients lost to follow‐up (in one study), and small sample sizes. There are difficulties with arranging RCTs of longer duration. However, future trials could aim at measuring seizure remission in the medium term to longer term, including after withdrawal of antiepileptic drugs. Cognitive function is an important outcome measure due to the concerns of cognitive impairment with BECTS. Antiepileptic drugs can contribute positively or negatively towards cognitive performance and this effect would be best measured in placebo‐controlled trials performed over a period of at least 12 months. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006779-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006779-sec-0022"></div> <div class="table" id="CD006779-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Clobazam compared with Carbamazepine for patients with BECTS</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: Patients with a clinical and EEG diagnosis of BECTS</b> </p> <p><b>Settings: Single centre in Cuba</b> </p> <p><b>Intervention: Clobazam</b> </p> <p><b>Comparison: Carbamazepine</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk on Carbamazepine</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk on Clobazam</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who are seizure free between 4‐40 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 100<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 100<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> </p> <p>(0.67 ‐ 1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<sup>2</sup> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>3</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who had seizure remission in the last 9 months of the study</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 100<sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 100<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b> </p> <p>(0.84 ‐ 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>5</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion of patients who discontinued treatment due to adverse events</b> </p> <p><b>(96 weeks trial period)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 per 1000<sup>6</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>56 per 1000<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.72</b> (0.05, 10.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>7</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One patient on clobazam discontinued due to rash whilst one on carbamazepine discontinued due to somnolence. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who reported adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 100<sup>8</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 100<sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.92</b> </p> <p>(0.59 ‐ 6.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>7</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion of patients with a particular or serious adverse event:</b> </p> <p>1. Vertigo</p> <p>2. Headache</p> <p>3. Somnolence</p> <p>4. Nausea/Vomiting</p> <p>5. Tremor</p> <p>6. Fatigue</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>17 per 100<sup>9</sup> </p> <p>11 per 100<sup>9</sup> </p> <p>17 per 100<sup>9</sup> </p> <p>56 per 1000<sup>9</sup> </p> <p>17 per 100<sup>9</sup> </p> <p>17 per 100<sup>9</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 100<sup>9</sup> </p> <p>16 per 100<sup>9</sup> </p> <p>12 per 100<sup>9</sup> </p> <p>20 per 1000<sup>9</sup> </p> <p>4 per 100<sup>9</sup> </p> <p>8 per 100<sup>9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>8</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The numbers in each group range from 1 to 5 patients. These are too small to compare if any statistical differences exist. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Changes in cognitive function testing from baseline (96 weeks trial period)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See<sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 baseline, 38 at end of trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>8</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; [other abbreviations, e.g. OR, etc] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The proportion of patients who were seizure free between 4 ‐ 40 weeks of the trial were 64% for those on carbamazepine and 66.7% for those on clobazam. We have rounded these off to 64 and 68 per 100 respectively. </p> <p><sup>2</sup> The study had 45 eligible participants but two were not randomised (no reasons given). </p> <p><sup>3</sup>The study was an open‐label study. There were inconsistencies in the reports regarding the numbers of excluded subjects e.g. in the carbamazepine group. </p> <p><sup>4</sup> The proportion of patients who had seizure remission during the last 9 months of the trial were 84% for those on carbamazepine and 88.9% for those on clobazam. We have rounded these off to 89 and 84 per 100 respectively. </p> <p><sup>5</sup> The study was an open‐label study. There were inconsistencies in the reports regarding the numbers of excluded subjects e.g. in the carbamazepine group. </p> <p><sup>6</sup> The proportion of patients who discontinued treatment due to adverse events was 4% for those in the carbamazepine group and 5.6% for those in the clobazam group. We have rounded these off to 40 and 56 per 1000 respectively. </p> <p><sup>7</sup> Reporting of adverse effects may have been affected as participants were not blinded. Elsewhere in the paper (footnotes of Table 1 in original paper), it was reported that five patients were excluded due to adverse events: three due to a severe rash, and two due to a combination of increasing seizures, the appearance of cognitive deficits, and reports from parents and teachers on a change in behaviour. It was not mentioned which arm of treatment these patients were randomised to, if this was done, and we were uncertain about whether they were considered to have dropped out. </p> <p><sup>8</sup> The proportion of patients who reported adverse events were 32% for those on carbamazepine and 16.7% for those on clobazam. We have rounded these off to 32 and 17 per 100 respectively. </p> <p><sup>9</sup> The proportion of patients reporting specific adverse events are listed under the subtitle Effects of Interventions in this review. </p> <p><sup>10</sup> The neuropsychometric evaluation explain how the patients were grouped into no, mild, moderate and severe learning difficulties. Four of 25 patients randomised to carbamazepine did not have baseline evaluations which could affect the estimates of the results. The results show that three patients of 18 in the clobazam and three of 21 in the carbamazepine groups had moderate to severe learning difficulties at baseline. At the end of the trial, no patients of 17 evaluated in the clobazam group and one of 21 in the carbamazepine group had moderate to severe learning difficulties. Unfortunately, this interesting report of an improvement in cognition did not benefit from adequate reporting and there were no mean cognitive scores provided. The cause of the apparent improvement was not corroborated with seizure remission. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006779-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Levetiracetam compared with Oxcarbazepine for patients with BECTS</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: Patients between three and 12 years old with clinical and EEG diagnosis of BECTS</b> </p> <p><b>Settings: Epilepsy outpatient clinics from three tertiary centres in Italy</b> </p> <p><b>Intervention: Levetiracetam</b> </p> <p><b>Comparison: Oxcarbazepine</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Illustrative comparative risks (95% CI)</p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Risk on Oxcarbazepine</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Risk on Levetiracetam</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who are seizure free at 3 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 100<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>100 per 100<sup>1</sup> </p> <p>(83 ‐ 121)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> (0.93 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who are seizure free at 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 100<sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>86 per 100<sup>3</sup> </p> <p>(60 ‐ 111)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.29</b> (0.89 to 1.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who discontinued treatment due to adverse events</b> </p> <p><b>(mean follow‐up period of 18.5 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1,000<sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1,000<sup>4</sup> </p> <p>(3 ‐ 612)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> (0.06 to 12.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion of patients with an adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 per 100<sup>6</sup> </p> <p>(2 ‐ 46)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>14 per 100<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.78</b> </p> <p>(0.15 to 4.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Changes in cognitive function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The outcome was not measured in the study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The proportion of patients who remained seizure free at three months after randomisation was 89% for those on oxcarbazepine and 100% for those on levetiracetam. We have rounded these off to 89 and 100 per 100 respectively. </p> <p><sup>2</sup> The study was unblinded. The age at randomisation in the two intervention groups differed causing heterogeneity that would influence the reported results. The small sample size produced a wide confidence interval resulting in imprecision of the estimated effect. </p> <p><sup>3</sup> The proportion of patients who remained seizure free at three months after randomisation was 67% for those on oxcarbazepine and 86% for those on levetiracetam. We have rounded these off to 67 and 86 per 100 respectively. </p> <p><sup>4</sup> The proportion of patients who discontinued treatment due to adverse events were 5.6% for those on oxcarbazepine and 4.8% for those levetiracetam. We have rounded these off to 56 and 48 per 1,000 respectively. </p> <p><sup>5</sup> The study was unblinded and the duration when interventions were used were not fixed. This makes comparison of adverse events difficult. </p> <p><sup>6</sup> The proportion of patients who reported adverse events were 11.1% for those on oxcarbazepine and 14.3% for those on levetiracetam. We have rounded these off to 11 and 14 per 100 respectively. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006779-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Carbamazepine compared with Topiramate for patients with BECTS</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: Patients between five and 15 years old with a diagnosis of BECTS</b> </p> <p><b>Settings: 12 centres in Korea</b> </p> <p><b>Intervention: Carbamazepine</b> </p> <p><b>Comparison: Topiramate</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Illustrative comparative risks (CI 95%)</p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Risk on Topiramate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Risk on Carbamazepine</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who are seizure free at 28 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>69 per 100<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>70 per 100<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> (0.77 to 1.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who discontinued treatment due to adverse events</b> </p> <p><b>(28 weeks trial period)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>10 per 100<sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>9 per 100<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> (0.36 to 3.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion of patients with an adverse event:</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported in the study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients with a particular or serious adverse event:</b> </p> <p>1. Somnolence</p> <p>2. Rash</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>12 per 100<sup>5</sup> </p> <p>2 per 100<sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>9 per 100<sup>5</sup> </p> <p>15 per 100<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (0.4‐3.9)</p> <p>8.59 (1.1 ‐ 66.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 (1 study)</p> <p>112 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes in cognitive function testing from baseline</b> </p> <p><b>(28 weeks trial period)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>low</b> </p> <p>⊕⊕⊝⊝<sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The pattern of neuropsychometric changes with topiramate seemed to be slightly worse than carbamazepine. When only those on minimum doses of both drugs were considered (n = 70), the scores for cognitive function were similar. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The proportion of patients who were seizure free at 28 weeks of the trial were 68.9% for those on topiramate and 70.3% for those on carbamazepine. We have rounded these off to 69 and 70 per 100 respectively. </p> <p><sup>2</sup>The study was observer‐blinded only. It had a large proportion of patients who were lost to follow‐up in whom the results were carried forward from the last observation. </p> <p><sup>3</sup> The proportion of patients who discontinued treatment due to adverse effects was 10.3% for those on topiramate and 9.3% for those on carbamazepine. We have rounded these off to 10 and 9 per 100 respectively. </p> <p><sup>4</sup> The study was observer blinded though, in this case, the incomplete outcome data does not affect the outcome. The wide confidence interval makes results imprecise. </p> <p><sup>5</sup> The proportion of patients who had somnolence as an adverse event was 12.1% for those on topiramate and 9.3% for those on carbamazepine. The proportion of patients who had rash as an adverse event was 1.7% for those on topiramate and 14.8% for those on carbamazepine. We have rounded these off to 12, 9, 2, and 15 per 100 respectively. </p> <p><sup>6</sup> Reporting of adverse effects may have been affected as participants were not blinded. Adverse events were not documented actively by caregivers </p> <p><sup>7</sup> There was a high loss to follow‐up which could affect the estimates of changes in cognitive function. Moreover, results were described according to the P value with no reports of the differences in mean change scores. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006779-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sulthiame compared with placebo for patients with BECTS</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: Patients between three and 10 years old with a diagnosis of BECTS</b> </p> <p><b>Settings: 26 centres in Europe</b> </p> <p><b>Intervention: Sulthiame</b> </p> <p><b>Comparison: Placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Illustrative comparative risks (95% CI)</p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Assumed risk</p> <p>(Placebo)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Corresponding risk</p> <p>(Sulthiame)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who are seizure free at 3 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 100<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>90 per 100<sup>1</sup> </p> <p>(59 ‐ 138)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.26</b> (1.48 to 3.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>2</sup> </p> <p><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who are seizure free at 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 100<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>68 per 100<sup>3</sup> </p> <p>(37 ‐ 126)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.63</b> (1.43 to 4.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>2</sup> </p> <p><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure after randomisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazard ratio 7.8 (2.66 to 22.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<sup>2</sup> </p> <p><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who discontinued treatment due to adverse events (over 6 months trial period)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 patients discontinued treatment due to adverse events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion of patients with an adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 100<sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>58 per 100<sup>4</sup> </p> <p>(36 ‐ 95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.35</b> (0.83 to 2.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<sup>5</sup> </p> <p><b><sup>moderate</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Changes in cognitive function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not measured in the study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The proportion of patients who remained seizure free at three months after randomisation was 40% for those on placebo and 90% for those on sulthiame. We have rounded these off to 40 and 90 per 100 respectively. </p> <p><sup>2</sup> The quality of evidence was downgraded given the limitations in the study of the small sample size affecting precision of results. </p> <p><sup>3</sup> The proportion of patients who remained seizure free at six months after randomisation was 26% for those on placebo and 68% for those on sulthiame. We have rounded these off to 26 and 68 per 100 respectively. </p> <p><sup>4</sup> The proportion of patients who reported adverse events were 58.1% for those on sulthiame and 42.9% for those on placebo. We have rounded these off to 58 and 43 per 100 respectively. </p> <p><sup>5</sup> Adverse events were recorded during assessments and not actively by caregivers. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006779-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006779-sec-0023"></div> <p>Benign Epilepsy with Centro Temporal Spikes (BECTS), also called Benign Rolandic Epilepsy, is one of the most common epilepsy syndromes in children, with an annual incidence between 6.2 and 10.7 per 100,000 children. BECTS is a well recognised seizure syndrome, with onset generally between the ages of four and 10 years (<a href="./references#CD006779-bbs2-0013" title="LudersH , LesserRP , DinnerDS , MorrisHH . III Benign focal epilepsy of childhood. In: LudersH , LesserRP editor(s). Electroclinical Syndromes. Berlin: Springer Verlag, 1987:609‐619. ">Luders 1987</a>). </p> <p>Children with BECTS have normal development, and no neurological deficits. However, as BECTS is very common, it can also coincidentally present in children with neurological problems. Seizures originate from the somatosensory and motor area in the lower rolandic region. Seizures tend to occur at night, and are brief. </p> <p>An attack typically starts with a somatosensory aura around the mouth, with unilateral paraesthesia of the tongue and mouth, followed by unilateral twitching of face, mouth, pharynx and larynx (<a href="./references#CD006779-bbs2-0012" title="LoiseauP , BeaussartM . The seizures of benign childhood epilepsy with Rolandic paroxysmal discharges. Epilepsia1973;14(4):381‐9. ">Loiseau 1973</a>). These can be associated with drooling and dysarthria. The seizure can propagate and involve the upper limb, and Todd's paralysis can follow. Consciousness is usually maintained, unless there is secondary generalisation. Secondary generalisation is rare in the day, but common at night (<a href="./references#CD006779-bbs2-0010" title="Commission of the International League against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia1989;30:389‐99. ">ILAE 1989</a>). The focal onset of seizures during sleep can easily be missed. Seizures are generally brief, lasting from a few seconds to a few minutes. Seizure frequency is low and around 10% to 20% cases experience only a single seizure. However, in about 20% of cases, seizures occur frequently (<a href="./references#CD006779-bbs2-0008" title="BoumaPA , BovenkerkAC , WestendorpRG , BrouwerOF . The course of benign partial epilepsy of childhood with centrotemporal spikes: a meta‐analysis. Neurology1997;48(2):430‐7. ">Bouma 1997</a>). Although in general children do not have long‐term problems associated with the seizures, some children show subtle cognitive problems (<a href="./references#CD006779-bbs2-0009" title="DeonnaT , ZesigerP , DavidoffV . Benign partial epilepsy of childhood, a longitudinal neuropsychological and EEG study of cognitive function. Developmental Medicine and Child Neurology2000;42:595‐603. ">Deonna 2000</a>). The transient, cognitive impairment seems to correlate with epileptic activity on the electroencephalogram (EEG) (<a href="./references#CD006779-bbs2-0014" title="MassaR , deSaint‐MartinA , CarcangiuR . EEG criteria predictive of cognitive complications in idiopathic focal epilepsy with rolandic spikes. Neurology2001;57:1071‐9. ">Massa 2001</a>). Some people consider BECTS as a mild form of epileptic encephalopathy in the spectrum of Landau‐Kleffner syndrome, and Electrical Status Epilepticus in Slow Wave Sleep. </p> <p>The EEG background is normal, though slower rhythms can be seen in the same areas as spikes. The characteristic EEG shows high voltage spikes in the centro temporal region on the left, right or bilaterally. These spikes can also be seen in children with no epilepsy, and tend to disappear spontaneously. A family history of epilepsy is common, and siblings and parents can show sharp waves or focal epileptiform activity on their EEGs, indicating a genetic predisposition in these children. </p> <p>Treatment is controversial, as the prognosis is deemed to be good. Antiepileptic drugs (AEDs) may control generalised seizures, but do not always help with the focal seizures. In most children with BECTS the epilepsy will resolve, whether treated or not. By 12 years 92% of children are in remission, and by 18 years 99.8% (<a href="./references#CD006779-bbs2-0008" title="BoumaPA , BovenkerkAC , WestendorpRG , BrouwerOF . The course of benign partial epilepsy of childhood with centrotemporal spikes: a meta‐analysis. Neurology1997;48(2):430‐7. ">Bouma 1997</a>). Many parents and children will choose not to start medication, especially if the seizures are infrequent or only occur at night. If treatment is required, most clinicians will choose carbamazepine as a first drug of choice, although clinical experience suggests that other AEDs may be effective. </p> <p>In this review, we planned to address the following questions.</p> <p> <ol id="CD006779-list-0001"> <li> <p>Does AED treatment make a difference to seizure remission rate and cognition?</p> </li> <li> <p>Which AED is the most effective in controlling seizures in children with BECTS?</p> </li> </ol> </p> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006779-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006779-sec-0024"></div> <p>To evaluate whether or not treatment with AEDs changes the short‐ or long‐term outcome of children with BECTS, or both. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006779-sec-0025" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006779-sec-0025"></div> <section id="CD006779-sec-0026"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006779-sec-0027"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) that compared the use of different AEDs, or compared the use of AEDs with placebo, or both were included. </p> </section> <section id="CD006779-sec-0028"> <h4 class="title">Types of participants</h4> <p>See: <a href="#CD006779-sec-0057">Differences between protocol and review</a> </p> <p> <ol id="CD006779-list-0002"> <li> <p>Children up to the age of 15 years old who presented with BECTS.</p> </li> <li> <p>Studies that reported participants with a diagnosis of BECTS.</p> </li> </ol> </p> </section> <section id="CD006779-sec-0029"> <h4 class="title">Types of interventions</h4> <p>Trials were included if they compared one treatment with another or with placebo. Specific drugs included carbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, sodium valproate, sulthiame, topiramate, and vigabatrin. </p> </section> <section id="CD006779-sec-0030"> <h4 class="title">Types of outcome measures</h4> <p>The outcome measures included:</p> <p> <ol id="CD006779-list-0003"> <li> <p>Short‐term outcome: (a) percentage of children who achieved seizure remission (i.e. seizure freedom) throughout the early period (e.g. three months) after randomisation; (b) time to first seizure after randomisation. </p> </li> <li> <p>Medium‐term outcome: (c) percentage of children who achieved seizure remission (i.e. seizure freedom) throughout the medium term (e.g. 12 months) after randomisation. </p> </li> <li> <p>Long‐term outcome: (d) percentage of children who remained seizure free after cessation of medication. </p> </li> <li> <p>Adverse effects of medication: (e) percentage of children who discontinued medication because of adverse effects, (f) percentage of children with a particular adverse event occurring e.g. increased day time sleepiness, rash, or other adverse effects which are considered to be serious. </p> </li> <li> <p>Cognitive functioning: (g) mean differences in neuropsychometric scores or resolution of specific cognitive difficulties e.g. dysgraphia on medication. </p> </li> </ol> </p> <p>Resolution of EEG abnormalities was not included as an outcome as the clinical manifestation of seizures is probably not related to persisting EEG abnormality, though cognitive functioning may be. </p> </section> </section> <section id="CD006779-sec-0031"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched the following databases:</p> <p> <ol id="CD006779-list-0004"> <li> <p>Cochrane Epilepsy Group Specialized Register (30 April 2013) using the search strategy outlined in <a href="./appendices#CD006779-sec-0051">Appendix 1</a>; </p> </li> <li> <p>CENTRAL (The Cochrane Central Register of Controlled Trials <i>The Cochrane Library</i>, 2013, Issue 4: (April 2013)), using the search strategy outlined in <a href="./appendices#CD006779-sec-0052">Appendix 2</a>; </p> </li> <li> <p>MEDLINE (Ovid, 1946 to 30 April 2013) using the search strategy outlined in <a href="./appendices#CD006779-sec-0053">Appendix 3</a>; </p> </li> <li> <p>SCOPUS (30 April 2013) using the search strategy outlined in <a href="./appendices#CD006779-sec-0054">Appendix 4</a>; </p> </li> <li> <p>ClinicalTrials.gov (30 April 2013) using the search terms: BECTS OR ((roland* OR sylvian OR centralopathic OR centrotemporal) AND (epilep* OR seizure*)) </p> </li> <li> <p>WHO International Clinical Trials Registry Platform ICTRP (30 April 2013) using the search terms: BECTS OR rolandic OR sylvian OR centralopathic OR centrotemporal  in the Title </p> </li> </ol> </p> <p>In addition, the references from articles relevant for inclusion were handsearched by all four review authors to ensure no studies were missed from the electronic searches. </p> </section> <section id="CD006779-sec-0032"> <h3 class="title" id="CD006779-sec-0032">Data collection and analysis</h3> <p>We independently assessed all trials that appeared potentially relevant for inclusion. All four review authors independently extracted the data collected from the individual studies and three authors (HJT,RG, CDG) assessed the risk of bias according to the domains of allocation concealment, blinding, and incomplete outcome data. We compared results and resolved any disagreements by conference. Where necessary, two of the review authors (JS, HJT) contacted the original authors for clarification and obtained individual patient data. We extracted the following data from the articles. </p> <p><b>Methodology</b> </p> <p> <ol id="CD006779-list-0005"> <li> <p>Case definition used. The diagnosis of BECTS is made clinically and electrophysiologically. There was variability in the studies reviewed on the descriptions of the case definition. We assumed a clinical diagnosis of BECTS was made when stated, and documented the definitions used. </p> </li> <li> <p>Method of randomisation and concealment.</p> </li> <li> <p>Method of (double) blinding.</p> </li> <li> <p>Whether or not patients had been excluded from the analysis, and if so the reasons for exclusion. If data were missing, we contacted the original authors for this information. </p> </li> </ol> </p> <p><b>Patient information</b> </p> <p> <ol id="CD006779-list-0006"> <li> <p>Number of participants allocated to each treatment group.</p> </li> <li> <p>Mean age of participants when seizures started.</p> </li> <li> <p>Mean age of participants when randomised.</p> </li> <li> <p>Distribution of sex of participants.</p> </li> <li> <p>Average frequency of seizures on randomisation (severity).</p> </li> <li> <p>Proportion of participants who remained seizure free for three months, 12 months or other identifiable length of time from time of initiation of randomised treatment. </p> </li> <li> <p>Time to first seizure after randomisation.</p> </li> <li> <p>Proportion of children who remained seizure free after cessation of randomised treatment.</p> </li> <li> <p>Proportion of participants who discontinued randomised treatment because of adverse effects. </p> </li> <li> <p>Proportion of participants with serious or specific adverse effects, such as day time sleepiness. </p> </li> <li> <p>Cognitive assessment, such as mean differences in cognitive function tests.</p> </li> </ol> </p> <p><b>Data analysis plan</b><br/> The primary analysis was intention‐to‐treat, and we included all randomised participants analysed in the treatment group to which they were allocated, irrespective of the treatment they actually received. The studies were assessed as to their risk of bias according to The Cochrane Collaboration's tool. The domains assessed were: selection bias (random sequence generation, allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), and attrition bias (incomplete outcome data). </p> <p>Clinical heterogeneity was assessed by reviewing clinical and methodological differences across trials, for example age and sex distribution, differences in seizure frequency/severity, and recruitment of participants in a general paediatric versus tertiary neurology setting. Subgroup regression analysis for heterogeneity was planned if there were at least 10 studies in a meta‐analysis and the pre‐specified characteristics included differences in age, drug dosages and length of treatment. The trial level treatment effect was analysed using risk ratio for dichotomous outcomes, difference in means for continuous outcomes and hazard ratio for time to event outcomes. Each estimate was presented with 95% confidence intervals. Meta‐analysis was performed for dichotomous outcomes using the Mantel‐Haenszel fixed‐effect methods, for continuous outcomes using the mean difference (MD) approach, and time‐to‐event data using the generic inverse variance method. In the case of missing data, a sensitivity analysis was performed for dichotomous outcomes where 'best‐case' and 'worst‐case' scenarios are considered with calculation of their respective relative risks. </p> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006779-sec-0033" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006779-sec-0033"></div> <section id="CD006779-sec-0034"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD006779-sec-0060" title="">Characteristics of included studies</a>. </p> <p>The literature search of the databases retrieved 77 references as follows: 19 from the Cochrane Epilepsy Group's Specialized Register, 29 from CENTRAL, 19 from MEDLINE, seven from SCOPUS, two from Clinical Trials, and one from WHO ICTRP. After eliminating duplicates, we found nine references to six studies that met our inclusion criteria. Out of these six studies, two studies were categorised as "awaiting further classification" and will be reviewed at the next update if sufficient information is obtained. Both these studies, <a href="./references#CD006779-bbs2-0005" title="BourgeoisB , BrownLW , PellockJM , BurokerM , GreinerM , GarofaloEA , et al. Gabapentin (Neurontin) monotherapy in children with benign childhood epilepsy with centrotemporal spikes (BECTS): a 36‐week, double‐blind, placebo‐controlled study. Epilepsia1998;39(Suppl 6):163, Abstract no: 5.067. ">Bourgeois 1998</a> and <a href="./references#CD006779-bbs2-0006" title="PellicciaA , FredianiS , FredianiT , LucarelliS . Rolandic epilepsy: comparison of allergen‐free diet and conventional treatments. Epilepsia2006;47(Suppl 3):68, Abstract no: p256. ">Pelliccia 2006</a>, were published abstracts which appeared suitable for inclusion. However, the information given was limited and the studies were not subsequently published as full‐length original articles. We contacted the authors for information about the study methodology and patient information required for this review but did not receive a reply. We intend to contact the authors before the next update of this review. This gave a total of four RCTs for inclusion in this present review with a total of 262 participants treated with six different AEDs, which were clobazam, carbamazepine, levetiracetam, oxcarbazepine, sulthiame, and topiramate. </p> <p>The characteristics of the participants in each of the studies are summarised under <a href="#CD006779-tbl-0005">Table 1</a>. </p> <div class="table" id="CD006779-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Participant characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant numbers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Male:Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*Age when seizures started (years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*Age when randomised (years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Frequency of seizures on randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clobazam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12:6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not clearly stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.22 +/‐ 1.3 (7‐11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not given (6 or more per month)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbamazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10:15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not clearly stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4 +/‐ 1.3 (7‐10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not given (6 or more per month)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Levetiracetam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11:10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 1.8 per month</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10:8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 1.5 per month</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0003" title="KangH‐C , EunB‐L , LeeCW , MoonHK , KimJ‐S , KimDW , et al. A multicenter, randomized, open‐labeled, clinical study to evaluate the effect on cognitive and behavioral function of topiramate compared with carbamazepine as monotherapy in children with benign rolandic epilepsy. Epilepsia2006;47 Suppl 4:138. KangHC , EunBL , Wu LeeC , Ku MoonH , KimJS , Wook KimD , et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia2007;48(9):1716‐23. LimK , KimHD , Korean BRE Study Group. Low‐dose topiramate compared with carbamazepine in treating benign rolandic epilepsy. Epilepsia2004;45 Suppl 7:322‐3. ">Kang 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbamazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32:22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not given</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32:26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not given</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sulthiame</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16:15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6 (1.9 ‐10.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2 (3.9 – 10.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 3 (2 – 10) during 6‐months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24:11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7 (3 – 10.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4 (3.1 – 10.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 2 (2 – 20) during 6‐months</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* Mean age (except study by <a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a>, where median age reported) </p> </div> </div> <p><a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> </p> <p>Andrade 2009 was a randomised, open‐label, parallel trial of 45 children with a diagnosis of BECTS following the clinical and electrographical criteria of the International League Against Epilepsy (ILAE) (<a href="./references#CD006779-bbs2-0010" title="Commission of the International League against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia1989;30:389‐99. ">ILAE 1989</a>). Children with six seizures per month or those in whom there was parental anxiety necessitating treatment were included. Exclusion criteria included children with metabolic conditions; those with a specific neurological diagnosis different to BECTS; pseudoseizures; patients on psychotropic medication; patients with active infection or cancer; and patients in whom previous treatment with either clobazam or carbamazepine was discontinued due to an adverse event (AE). Patients were randomised to treatment with either clobazam or carbamazepine. The study duration was 96 weeks, with an initial six weeks when medication was gradually increased, followed by 90 weeks on a maintenance dose. Patients were randomised to either receive clobazam with a starting dose of 1 mg/kgm/day, increased as tolerated to a maximum of 2 mg/kgm/day, or carbamazepine starting at 10 mg/kgm/day divided in three doses, and increased up to a maximum of 30 mg/kgm/day. Doses were reduced in the presence of non‐tolerable adverse effects. There were no significant differences in age or weight between the two groups. The criteria for exit from the study included patients on the maximum dosage without control of seizures, inability to tolerate the lowest dose required, recurrence of seizures after reducing the dose because of side effects, or patients/families wishing to discontinue the study. Non‐adherent patients also had the doses of the treatment drug gradually reduced until discontinuation after four weeks. Forty‐five patients (31 male, 14 female) were eligible but two were not randomised for reasons that were unclear. One of the patients randomised to clobazam, and three patients randomised to carbamazepine did not complete the study. Outcomes reported included seizure freedom during the first four weeks, between week four and week 40, and at nine months of treatment. Other outcomes were the number of patients with a reduction in seizure frequency of 50% or more at four weeks, adverse events, educational, neuropsychological, and behavioural assessments, and satisfaction with treatment. </p> <p><a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a> </p> <p>Coppola 2007 was a randomised, open‐label, parallel, multicentre group trial involving 39 children. The inclusion criteria were patients between three and 12 years of age with a new diagnosis of BECTS according to the ILAE classification and who had not been previously treated. All participants had frequent or recurrent partial motor seizures, with or without generalisation during wakefulness in the last six months, an EEG consisting of focal or multifocal centrotemporal spikes increasing in frequency during sleep with normal background activity, and brain magnetic resonance imaging (MRI) with normal or slightly abnormal findings, and no neurological or mental deficits. Exclusion criteria included: poor compliance by parents/caregivers in keeping records of seizure frequency; adverse events or in undergoing requested clinical controls; progressive neurological and/or systemic disease; and associated pseudoseizures. Patients were seen every three months prior to randomisation for recording of awake and sleep EEGs, monitoring of drug levels, haematological, renal and liver function tests. Randomisation to levetiracetam or oxcarbazepine monotherapy was performed and the dose initiated at 5 mg/kg/day, followed by titration at 5 mg/kg every three days up to a dose of 20 mg/kg/day according to tolerance. Additional increments were allowed up to 30 mg/kg once or twice daily for levetiracetam and 35 mg/kg once or twice a daily for oxcarbazepine. From additional data supplied by the authors, two participants (one from each group) were lost to follow‐up after three months without any specified reasons, but they did not have any seizures during the treatment period. These patients' data were imputed as seizure occurrences by the authors. Patients were followed up for a mean period of 18.5 months (range three to 24 months). Outcomes reported were the percentage of patients with complete seizure freedom after the follow‐up period (mean time of 18.5 months, range 12 ‐ 24 months), and adverse effects of drug treatment. The authors provided us with details regarding the proportion of patients who were seizure free three and 12 months after randomisation. </p> <p><a href="./references#CD006779-bbs2-0003" title="KangH‐C , EunB‐L , LeeCW , MoonHK , KimJ‐S , KimDW , et al. A multicenter, randomized, open‐labeled, clinical study to evaluate the effect on cognitive and behavioral function of topiramate compared with carbamazepine as monotherapy in children with benign rolandic epilepsy. Epilepsia2006;47 Suppl 4:138. KangHC , EunBL , Wu LeeC , Ku MoonH , KimJS , Wook KimD , et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia2007;48(9):1716‐23. LimK , KimHD , Korean BRE Study Group. Low‐dose topiramate compared with carbamazepine in treating benign rolandic epilepsy. Epilepsia2004;45 Suppl 7:322‐3. ">Kang 2007</a> </p> <p>Kang 2007 was a randomised, observer‐blinded, open‐label, parallel, multicentre trial of 112 patients. Participants, aged between five to 15 years old, were eligible if they had clinical and EEG findings compatible with benign rolandic epilepsy, at least two partial‐onset seizures during six months at baseline, a normal MRI which confirmed the absence of a progressive lesion, and at least one of the following criteria: parent and/or patient wanted to take AEDs; daytime seizures; one or more episodes of a convulsive seizure during six months. Amongst the exclusion criteria were patients previously on topiramate or carbamazepine; cognitive impairment interfering with the cognitive testing procedure; history of poor compliance with AED treatment or inability to maintain a seizure calendar. The study included a baseline phase of six months followed by a one week screening phase during which eligibility was determined. The AED doses were then escalated to the minimum target doses over a period of four weeks. Topiramate was introduced at a dose of 12.5 mg/day with the minimum target dose of 50 mg/day in patients &lt; 30 kg and 75 to 100 mg/day in patients &gt; 30 kg. Carbamazepine was started at a dose of 10 mg/kg/day and the minimum target dose was 20 mg/kg/day. Additional dose increments were allowed up to a maximum of 4 mg/kg/day for topiramate and 30 mg/kg/day for carbamazepine until 22 weeks. The drugs were maintained at a stable dose until completion of the study at 28 weeks. Patients in both groups were similar with regard to known prognostic factors. Thirteen participants dropped out from the topiramate group (six due to adverse effects, seven due to non‐drug‐related causes) and 11 from the carbamazepine group (five due to adverse effects, six due to non‐drug‐related causes). For patients who withdrew early from the study, the last observation reported was carried forward in the analysis. The primary study objective was to evaluate cognitive and behavioural effects of these AEDs by measuring changes in neuropsychological test batteries and behaviour‐rating scales performed at baseline and 28 weeks after treatment. Data regarding treatment‐emergent adverse effects and the percentage of patients who were seizure free after 28 weeks were recorded. This study was supported by a grant of Janssen, Korea Limited, manufacturers of topiramate. </p> <p><a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a> </p> <p>Rating 2000 was a randomised, double‐blind, placebo‐controlled multicentre trial of 66 patients with a diagnosis of BECTS. The case definition was not specifically defined. All patients were between three and 11 years of age, weighed 10 to 50 kilograms, and had experienced two or more seizures six months prior to the study admission. Amongst the exclusion criteria were patients with severe organic diseases; a history of mental illness; relevant hypersensitivity; or relevant renal, thyroid, or hepatic dysfunction; as well as those who had prior treatment for epilepsy after the sixth month of life. Eligible patients were randomised to receive either sulthiame or a placebo. The study consisted of a six‐month historic baseline period and a six‐month double‐blind treatment phase. The dose of sulthiame was approximately 5 mg/kg/day in three divided doses and this was given without titration. Patients in the treatment and control groups were similar with regard to known prognostic factors. Both the recipients and assessors were blinded. Two patients withdrew from the sulthiame group whilst four withdrew from the placebo group. Two from the placebo group withdrew within the first week due to parental wishes and in four patients (two from each group), the trial was terminated in advance after a planned adaptive interim analysis demonstrated superiority of the intervention. This analysis was performed on an intention‐to‐treat basis after 60 patients had completed the trial with an alpha value of 0.05 and P values of &lt;= 0.0299 or &gt; 0.3. The missing data were imputed as seizure reoccurrences. On top of this, four patients from the sulthiame group and one patient from the placebo group had final data from the last visit assessed just days prior to the end of the experimental period. These patients were seizure free but their data have also been imputed as seizure occurrences by the authors. Outcomes reported were 1) the treatment failure events (TFEs) during the period of the trial, defined as first seizure after a seven‐day run‐in period post randomisation, intolerable adverse events, development of another epileptic syndrome, and termination from the trial by their parents or themselves, and 2) changes in EEG recordings over time. </p> </section> <section id="CD006779-sec-0035"> <h3 class="title">Risk of bias in included studies</h3> <p>The overall risk of bias in three of the four included studies for the outcomes of seizure remission, adverse effects and cognition was judged to be high. Only one of the three included studies (<a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a>) was found to have a low risk of bias for the outcomes of seizure remission and adverse effects. Although there was an adequate method of randomisation described, the results in the <a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a> study showed that the ages at seizure onset and at randomisation were greater in those receiving levetiracetam (mean age of 10.5 years) than oxcarbazepine (mean age of 8.4 years) probably due to the small sample size. This could lead to an overestimation of the effects of levetiracetam on seizure remission. </p> <section id="CD006779-sec-0036"> <h4 class="title">Allocation</h4> <p>In the study by <a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a>, there was adequate sequence generation (block randomisation) and allocation concealment (sealed envelopes). The sequence generation of patients to their respective interventions (computer‐generated randomisation) was considered to have a low risk of bias in the studies by <a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> and <a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a> though information about allocation concealment was not provided in both studies. Additionally, <a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> reports that two patients were not randomised but reasons for this were not provided. In the study by <a href="./references#CD006779-bbs2-0003" title="KangH‐C , EunB‐L , LeeCW , MoonHK , KimJ‐S , KimDW , et al. A multicenter, randomized, open‐labeled, clinical study to evaluate the effect on cognitive and behavioral function of topiramate compared with carbamazepine as monotherapy in children with benign rolandic epilepsy. Epilepsia2006;47 Suppl 4:138. KangHC , EunBL , Wu LeeC , Ku MoonH , KimJS , Wook KimD , et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia2007;48(9):1716‐23. LimK , KimHD , Korean BRE Study Group. Low‐dose topiramate compared with carbamazepine in treating benign rolandic epilepsy. Epilepsia2004;45 Suppl 7:322‐3. ">Kang 2007</a>, the randomisation process and allocation concealment were not described. </p> </section> <section id="CD006779-sec-0037"> <h4 class="title">Blinding</h4> <p>One study was double‐blinded (<a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a>), one observer‐blinded (<a href="./references#CD006779-bbs2-0003" title="KangH‐C , EunB‐L , LeeCW , MoonHK , KimJ‐S , KimDW , et al. A multicenter, randomized, open‐labeled, clinical study to evaluate the effect on cognitive and behavioral function of topiramate compared with carbamazepine as monotherapy in children with benign rolandic epilepsy. Epilepsia2006;47 Suppl 4:138. KangHC , EunBL , Wu LeeC , Ku MoonH , KimJS , Wook KimD , et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia2007;48(9):1716‐23. LimK , KimHD , Korean BRE Study Group. Low‐dose topiramate compared with carbamazepine in treating benign rolandic epilepsy. Epilepsia2004;45 Suppl 7:322‐3. ">Kang 2007</a>), and two were open‐label unblinded studies (<a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> and <a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a>). The method in <a href="./references#CD006779-bbs2-0003" title="KangH‐C , EunB‐L , LeeCW , MoonHK , KimJ‐S , KimDW , et al. A multicenter, randomized, open‐labeled, clinical study to evaluate the effect on cognitive and behavioral function of topiramate compared with carbamazepine as monotherapy in children with benign rolandic epilepsy. Epilepsia2006;47 Suppl 4:138. KangHC , EunBL , Wu LeeC , Ku MoonH , KimJS , Wook KimD , et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia2007;48(9):1716‐23. LimK , KimHD , Korean BRE Study Group. Low‐dose topiramate compared with carbamazepine in treating benign rolandic epilepsy. Epilepsia2004;45 Suppl 7:322‐3. ">Kang 2007</a> where recipients were not blinded would have minimal influence on the study's primary outcome measure of cognition. However, the risk of bias on reported outcomes of seizure remission and adverse drug effects from participants and caregivers would be high. </p> </section> <section id="CD006779-sec-0038"> <h4 class="title">Incomplete outcome data</h4> <p>All participants were analysed in the groups to which they were randomised. All four studies reported patients withdrawing from their allocated treatments. The number of patients with incomplete outcome data was small and balanced across intervention groups in <a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a> and <a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a>. <a href="./references#CD006779-bbs2-0003" title="KangH‐C , EunB‐L , LeeCW , MoonHK , KimJ‐S , KimDW , et al. A multicenter, randomized, open‐labeled, clinical study to evaluate the effect on cognitive and behavioral function of topiramate compared with carbamazepine as monotherapy in children with benign rolandic epilepsy. Epilepsia2006;47 Suppl 4:138. KangHC , EunBL , Wu LeeC , Ku MoonH , KimJS , Wook KimD , et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia2007;48(9):1716‐23. LimK , KimHD , Korean BRE Study Group. Low‐dose topiramate compared with carbamazepine in treating benign rolandic epilepsy. Epilepsia2004;45 Suppl 7:322‐3. ">Kang 2007</a> reported 24 (21.4%) patients lost to follow‐up due to adverse effects and non‐drug‐related causes. There were discrepancies within the report of the number of patients who withdrew from their assigned treatment group in <a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> and five patients were reported to have been excluded although it is unclear when in the study this took place. In <a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a>, <a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a>, and <a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a>, participants who withdrew early were imputed by the authors as having had seizures. In <a href="./references#CD006779-bbs2-0003" title="KangH‐C , EunB‐L , LeeCW , MoonHK , KimJ‐S , KimDW , et al. A multicenter, randomized, open‐labeled, clinical study to evaluate the effect on cognitive and behavioral function of topiramate compared with carbamazepine as monotherapy in children with benign rolandic epilepsy. Epilepsia2006;47 Suppl 4:138. KangHC , EunBL , Wu LeeC , Ku MoonH , KimJS , Wook KimD , et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia2007;48(9):1716‐23. LimK , KimHD , Korean BRE Study Group. Low‐dose topiramate compared with carbamazepine in treating benign rolandic epilepsy. Epilepsia2004;45 Suppl 7:322‐3. ">Kang 2007</a>, the last observation reported was carried forward and the participants were considered as seizure free. </p> <p>A sensitivity analysis (reported in <a href="#CD006779-tbl-0006">Table 2</a>) was performed with best, reported, and worst scenarios to determine the effect of incomplete outcome data on estimates of seizure remission. In <a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a>, patients only withdrew three months after randomisation and hence, the outcome at three months would not be affected. </p> <div class="table" id="CD006779-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Best outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Best outcome RR (CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported</p> <p>outcome RR (CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worst outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worst outcome RR (CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seizure free at 4‐40 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clobazam</p> <p>Carbamazpine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/18 = 72%</p> <p>16/25 = 64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13</p> <p>(0.75 ‐ 1.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/18 = 66.7%</p> <p>16/25 = 64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04</p> <p>(0.67 ‐ 1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/18 = 66.7%</p> <p>18/25 = 72.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93</p> <p>(0.62 ‐ 1.39)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seizure remission in last 9 months of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clobazam</p> <p>Carbamazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/18=94.4%</p> <p>21/25 = 84%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12</p> <p>(0.92 ‐ 1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/18 = 88.9%</p> <p>21/25 = 84%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06</p> <p>(0.84, 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/18 = 88.9%</p> <p>22/25 = 88%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01</p> <p>(0.81 ‐ 1.26)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seizure remission at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Levetiracetam</p> <p>Oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/21 = 100%</p> <p>16/18 = 88.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13</p> <p>(0.93 ‐ 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/21 = 100%</p> <p>16/18 = 88.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13</p> <p>(0.93 ‐ 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/21 = 100%</p> <p>16/18 = 88.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13</p> <p>(0.93 ‐ 1.36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seizure remission at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Levetiracetam</p> <p>Oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/21 = 90.5%</p> <p>12/18 = 66.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.36</p> <p>(0.95 ‐ 1.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/21=85.7%</p> <p>12/18 = 66.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29</p> <p>(0.89 ‐ 1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/21 = 85.7%</p> <p>13/18 = 72.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19<br/> (0.85 ‐ 1.66) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0003" title="KangH‐C , EunB‐L , LeeCW , MoonHK , KimJ‐S , KimDW , et al. A multicenter, randomized, open‐labeled, clinical study to evaluate the effect on cognitive and behavioral function of topiramate compared with carbamazepine as monotherapy in children with benign rolandic epilepsy. Epilepsia2006;47 Suppl 4:138. KangHC , EunBL , Wu LeeC , Ku MoonH , KimJS , Wook KimD , et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia2007;48(9):1716‐23. LimK , KimHD , Korean BRE Study Group. Low‐dose topiramate compared with carbamazepine in treating benign rolandic epilepsy. Epilepsia2004;45 Suppl 7:322‐3. ">Kang 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seizure remission at 28 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbamazepine</p> <p>Topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38/54 = 70.3%</p> <p>27/58 = 46.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.51</p> <p>(1.09 ‐ 2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38/54 = 70.3%</p> <p>40/58 = 68.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02</p> <p>(0.8 ‐ 1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/54 = 50%</p> <p>40/58 = 68.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72</p> <p>(0.53 ‐ 1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seizure remission at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sulthiame</p> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/31 = 93.5%</p> <p>14/35 = 40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.34</p> <p>(1.54 ‐ 3.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/31 = 90.3%</p> <p>14/35 = 40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.26</p> <p>(1.48 ‐ 3.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/31 = 90.3%</p> <p>16/35 = 45.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.98</p> <p>(1.35 ‐ 2.89)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seizure remission at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sulthiame</p> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/31 = 87.1%</p> <p>9/35 = 25.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.39</p> <p>(1.9 ‐ 6.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/31 = 67.7%</p> <p>9/35 = 25.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.63</p> <p>(1.43 ‐ 4.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/31 = 67.7%</p> <p>14/35 = 40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.69</p> <p>(1.06 ‐ 2.72)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>In the sensitivity analysis, "best outcome" imputes an outcome for missing data with replacement values favouring the intervention reported to have the higher relative risk of seizure remission, whilst "worst outcome" imputes values for missing data favouring the intervention reported to have the lower relative risk of seizure remission. The analysis shows that seizure remission was not influenced by the withdrawal of participants in the studies by <a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a>, <a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a> and <a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a>. This was because the numbers were small and were balanced between the groups. In <a href="./references#CD006779-bbs2-0003" title="KangH‐C , EunB‐L , LeeCW , MoonHK , KimJ‐S , KimDW , et al. A multicenter, randomized, open‐labeled, clinical study to evaluate the effect on cognitive and behavioral function of topiramate compared with carbamazepine as monotherapy in children with benign rolandic epilepsy. Epilepsia2006;47 Suppl 4:138. KangHC , EunBL , Wu LeeC , Ku MoonH , KimJS , Wook KimD , et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia2007;48(9):1716‐23. LimK , KimHD , Korean BRE Study Group. Low‐dose topiramate compared with carbamazepine in treating benign rolandic epilepsy. Epilepsia2004;45 Suppl 7:322‐3. ">Kang 2007</a>, the excessive drop‐out rate in this study could affect the estimate of seizure remission in the topiramate and carbamazepine groups. </p> </div> </div> </section> </section> <section id="CD006779-sec-0039"> <h3 class="title" id="CD006779-sec-0039">Effects of interventions</h3> <p>See: <a href="./full#CD006779-tbl-0001"><b>Summary of findings for the main comparison</b> </a>; <a href="./full#CD006779-tbl-0002"><b>Summary of findings 2</b> </a>; <a href="./full#CD006779-tbl-0003"><b>Summary of findings 3</b> </a>; <a href="./full#CD006779-tbl-0004"><b>Summary of findings 4</b> </a> </p> <p>The characteristics of the participants are summarised under <a href="#CD006779-tbl-0005">Table 1</a>. </p> <section id="CD006779-sec-0040"> <h4 class="title">Clobazam versus Carbamazepine</h4> <p>There was one study (<a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a>). </p> <p>Effects on seizure remission from 4 ‐ 40 weeks after randomisation: 12 (66.7%) of 18 patients treated with clobazam were seizure free during this period compared with 16 (64%) of 25 patients treated with carbamazepine, giving an RR (relative risk) of 1.04 with 95% CI of 0.67 ‐ 1.62. </p> <p>Effects on seizure remission in the last nine months of the study period (total 96 weeks): 16 (88.9%) of 18 patients treated with clobazam had no seizures during this period of the study compared to 21 (84%) of 25 patients treated with carbamazepine, giving an RR of 1.06 with 95% CI of 0.84 ‐ 1.34. </p> <p>Time to first seizure after randomisation was not reported as an outcome in this study.</p> <p>Effects on seizure remission after cessation of medication were not reported as an outcome in this study. </p> <p>Adverse effects of medication:three (16.7%) of the 18 patients on clobazam and eight (32%) of the 25 patients on carbamazepine reported 35 and 76 different adverse effects respectively. For clobazam and carbamazepine groups respectively, these include vertigo (16.7% vs. 20%), headaches (11.2% vs. 20%), somnolence (16.7% vs. 12%), nausea/vomiting (16.7% vs. 12%), diarrhoea (5.6% vs. 4%), tremor (16.7% vs. 4%), and fatigue (16.7% vs. 8%). One patient each from the clobazam (5.6%) and carbamazepine groups (4%) withdrew from the study due to rash and somnolence respectively. </p> <p>Effects on cognitive functioning: Neuropsychometric evaluation was performed using the Weschler intelligence scale for children at baseline and at the end of the study. The numbers of patients categorised as having no, mild, moderate or severe learning difficulties were reported at both time points though three patients in the group assigned to carbamazepine did not have an evaluation. At baseline, there were three (16.7%) of 18 patients in the clobazam group with moderate to severe learning difficulties and three (14.3%) of 21 in the carbamazepine group. This difference was not significant (Mann Whitney test, p=0.4). There was no significant difference observed at the end of study between groups, although an improvement was noted: none of 17 patients assessed in the clobazam group assessed and one (4.8%) of 21 patients in the carbamazepine group were shown to have moderate to severe learning difficulties. </p> </section> <section id="CD006779-sec-0041"> <h4 class="title">Levetiracetam versus Oxcarbazepine</h4> <p>There was one study (<a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a>). </p> <p>Effects on seizure remission (seizure freedom) for three months after randomisation: all 21 (100%) patients treated with levetiracetam were seizure free during the three months after randomisation compared with 16 (88.9%) out of 18 patients treated with oxcarbazepine, giving a RR of 1.13 with 95% CI of 0.93 ‐ 1.36. </p> <p>Effects on seizure remission (seizure freedom) for 12 months after randomisation: 18 (88.7%) out of 21 patients treated with levetiracetam were seizure free during the 12 months after randomisation compared with 12 (66.7%) of 18 patients treated with oxcarbazepine, giving a RR of 1.29 with 95% CI of 0.89 ‐ 1.86. </p> <p>Time to first seizure after randomisation was not reported as an outcome in this study.</p> <p>Effects on seizure remission after cessation of medication were not reported as an outcome in this study. </p> <p>Adverse effects of medication: one (4.8%) of 21 patients on levetiracetam and one (5.6%) of 18 on oxcarbazepine discontinued medication because of adverse effects. Three (14.3%) children on levetiracetam reported adverse effects, which included mild decrease in appetite (2), and moderate decrease in appetite with daily frontal headaches (1). Two (11.1%) patients on oxcarbazepine reported adverse effects, which included headache (1), and sedation (1). </p> <p>Effects on cognitive functioning were not reported as an outcome in this study.</p> </section> <section id="CD006779-sec-0042"> <h4 class="title">Carbamazepine versus Topiramate</h4> <p>There was one study (<a href="./references#CD006779-bbs2-0003" title="KangH‐C , EunB‐L , LeeCW , MoonHK , KimJ‐S , KimDW , et al. A multicenter, randomized, open‐labeled, clinical study to evaluate the effect on cognitive and behavioral function of topiramate compared with carbamazepine as monotherapy in children with benign rolandic epilepsy. Epilepsia2006;47 Suppl 4:138. KangHC , EunBL , Wu LeeC , Ku MoonH , KimJS , Wook KimD , et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia2007;48(9):1716‐23. LimK , KimHD , Korean BRE Study Group. Low‐dose topiramate compared with carbamazepine in treating benign rolandic epilepsy. Epilepsia2004;45 Suppl 7:322‐3. ">Kang 2007</a>). </p> <p>Effects on seizure remission (seizure freedom) for 28 weeks after randomisation: 40 (68.9%) of the 58 patients randomised to receive topiramate and 38 (70.3%) of the 54 patients randomised to receive carbamazepine were seizure free during the experimental period of 28 weeks, giving a RR 1.02 with 95% CI of 0.8 ‐ 1.3. </p> <p>Effects on seizure remission for three months after randomisation were not reported as an outcome in this study. </p> <p>Effects on seizure remission for 12 months after randomisation were not reported as an outcome in this study. The double‐blind phase was only for 28 weeks. </p> <p>Time to first seizure after randomisation was not reported as an outcome in this study.</p> <p>Effects on seizure remission after cessation of medication were not reported as an outcome in this study. </p> <p>Adverse effects of medication: six (10.3%) of the 58 patients treated with topiramate and five (9.3%) of the 54 patients treated with carbamazepine discontinued medication because of adverse effects. The adverse effects in the six on topiramate were anhidrosis (3), anorexia (1), enuresis (1), and rash (1), whilst the adverse effects in the five on carbamazepine were rash (4) and tiredness (1). Amongst all 58 patients treated with topiramate, seven had somnolence, three anhidrosis, two psychomotor slowing, two anorexia, two gastrointestinal disturbance, two paresthesia, and one each had dizziness, tiredness, enuresis, and rash. Amongst all 54 patients treated with carbamazepine, eight had a rash, five somnolence, five tiredness, five increased appetite, and one dizziness. </p> <p>Effects on cognitive functioning: a neuropsychological test battery consisted of Bender Gestalt Test (BGT) and KEDI‐WISC (Korean Educational Developmental Institute – Wechsler Intelligence Scale for Children), the Korean version of WISC‐R. Eighty eight patients completed the trial and had neuropsychological testing; 45 in the topiramate group and 43 in the carbamazepine group.The results were reported as either an improvement or a worsening of scores from baseline to end point with comparisons made between topiramate and carbamazepine. Statistical analyses was made using the Student's t‐test to compare changes over time for the two treatment groups. The authors reported p values and 95% confidence intervals based on the t‐distribution and pooled estimate of variance. Although there were negative and positive trends in the cognitive variables measured for the two AEDs, only two out of twelve subtests showed statistical significance. The arithmetic subtest showed more deterioration in those on topiramate (p = 0.037; 95% CI: 0.07–2.12) whilst the maze test showed a greater improvement in those on carbamazepine (p = 0.026; 95% CI 0.20‐3.10). When the 30 patients on topiramate and the 40 on carbamazepine who had maintained the minimum target doses were compared, the scores were similar between the two groups, with only object assembly showing statistically significant improvement in those on topiramate compared to worsening scores in those on carbamazepine (p=0.006; 95% CI: 0.20‐4.10). </p> </section> <section id="CD006779-sec-0043"> <h4 class="title">Sulthiame versus placebo</h4> <p>There was one study (<a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a>). </p> <p>Effects on seizure remission (seizure freedom) for three months after randomisation: The study reported treatment failure events as the primary effectiveness variable. The study authors kindly provided individual patient data on seizure remission at three and six months. Twenty eight (90.3%) out of 31 patients treated with sulthiame were seizure free during the first three months compared with 14 (40%) out of 35 patients on placebo, giving a RR of 2.26 with 95% CI of 1.48 ‐ 3.44. </p> <p>Effects on seizure remission (seizure freedom) for six months after randomisation: 21 (67.7%) out of 31 patients treated with sulthiame were seizure free during the six‐month trial period compared with nine (25.7%) out of 35 patients on placebo, giving a RR of 2.63 with 95% CI of 1.43 ‐ 4.86. </p> <p>Effects on seizure remission for 12 months after randomisation were not reported as an outcome in this study. The double‐blind phase was only for six months. </p> <p>Time to first seizure after randomisation: The authors provided us with the estimated log hazard ratio and standard error using the Cox analysis model. The hazard ratio was 7.8 with 95% CI of 2.66 ‐ 22.87. </p> <p>Effects on seizure remission using Kaplan‐Meier analysis: Following our correspondence with the authors, they used the Kaplan‐Meier analysis to account for patients who terminated or were analysed prior to the end of the study. Please refer to <a href="#CD006779-fig-0001">Figure 1</a>. The proportion of patients treated with sulthiame who remained seizure free were 1.000 on Day 28, 0.935 at three months, and 0.902 at six months whilst that of patients on placebo were 0.800 on Day 28, 0.457 at three months, and 0.396 at six months. </p> <div class="figure" id="CD006779-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Sulthiame versus placebo (Rating 2000): Kaplan‐Meier plot of seizure free patients" data-id="CD006779-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Sulthiame versus placebo (<a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a>): Kaplan‐Meier plot of seizure free patients </p> </div> </div> </div> <p>Effects on seizure remission after cessation of medication were not reported as an outcome in this study. </p> <p>Adverse effects of medication: None of the patients in this study discontinued medication because of adverse effects. Eighteen (58.1%) of the 31 children on sulthiame and fifteen (42.9%) of the 35 children on placebo reported adverse events. The adverse effects which were reported more than once per group included two on sulthiame who reported fatigue, two others on sulthiame who reported loss of strength, and two on placebo who reported leukopenia. </p> <p>Effects on cognitive functioning were not reported as an outcome in this study.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006779-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006779-sec-0044"></div> <p>Despite the fact that BECTS is one of the most common epilepsy syndromes in school‐aged children, we found only four RCTs suitable for our analysis containing 262 participants. </p> <p>All four RCTs in this review used different methodologies. The quality of the evidence ranged from moderate to very low quality. Only the trial by <a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a> was judged to be of a sufficient quality. However, the weakness in <a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a> was its small sample size (66 patients) which affects the precision of the result. The other three trials (<a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a>, <a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a> and <a href="./references#CD006779-bbs2-0003" title="KangH‐C , EunB‐L , LeeCW , MoonHK , KimJ‐S , KimDW , et al. A multicenter, randomized, open‐labeled, clinical study to evaluate the effect on cognitive and behavioral function of topiramate compared with carbamazepine as monotherapy in children with benign rolandic epilepsy. Epilepsia2006;47 Suppl 4:138. KangHC , EunBL , Wu LeeC , Ku MoonH , KimJS , Wook KimD , et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia2007;48(9):1716‐23. LimK , KimHD , Korean BRE Study Group. Low‐dose topiramate compared with carbamazepine in treating benign rolandic epilepsy. Epilepsia2004;45 Suppl 7:322‐3. ">Kang 2007</a>) did not have or report allocation concealment and were not double‐blinded. The study by <a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> had a small sample size (43 patients) and was an open‐label unblinded trial with some inaccuracies in the reporting. The study by <a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a> had a small sample size (39 patients) and was an open‐label unblinded trial without a fixed follow‐up period. The study by <a href="./references#CD006779-bbs2-0003" title="KangH‐C , EunB‐L , LeeCW , MoonHK , KimJ‐S , KimDW , et al. A multicenter, randomized, open‐labeled, clinical study to evaluate the effect on cognitive and behavioral function of topiramate compared with carbamazepine as monotherapy in children with benign rolandic epilepsy. Epilepsia2006;47 Suppl 4:138. KangHC , EunBL , Wu LeeC , Ku MoonH , KimJS , Wook KimD , et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia2007;48(9):1716‐23. LimK , KimHD , Korean BRE Study Group. Low‐dose topiramate compared with carbamazepine in treating benign rolandic epilepsy. Epilepsia2004;45 Suppl 7:322‐3. ">Kang 2007</a> was an open‐label, observer‐blinded study with a high drop‐out rate. All three trials compared different AED treatments. Due to the varying treatments and methodologies, a meta‐analysis could not be performed. </p> <p>After extracting the required data, the trial by <a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a> comparing sulthiame with placebo found that significantly more patients on sulthiame were seizure free for three and six months after treatment compared to those on placebo. The time to first seizure after randomisation was also longer for patients on sulthiame. Sulthiame was well tolerated with no significant difference between sulthiame and placebo for withdrawal due to adverse effects. </p> <p>The other three trials comparing carbamazepine with clobazam, levetiracetam with oxcarbazepine, and topiramate with carbamazepine, were of a low to very low quality. The wide confidence intervals in the point estimates for seizure remission show that there is insufficient information about the superiority of the AEDs compared. The effects on cognitive functioning were assessed in the trial between topiramate and carbamazepine and in the study between carbamazepine and clobazam. In the former, this found changes in a few subtests to be significantly worse in those on topiramate but outcomes were similar when only individuals on minimum target doses were compared. This study did not report the actual differences between the neuropsychometric scores. In the latter study, there was no significant difference found between the groups in the moderate/severe categories of learning disability and neuropsychometric scores were not reported. </p> <p>The assessment of adverse events reported whilst on AEDs taken from RCTs alone, as performed in this review, does not provide a comprehensive range of adverse events especially those that may be rare but important. The possibility of AEDs resulting in worsening of seizures was not examined in this review. Reliable data about cognitive effects is currently lacking. When considering the cognitive effects in BECTS, it would be useful to assess data from studies which compare no treatment/placebo with an effective AED. There was a lag‐time of more than one year between the search date and the publication of the review. This may introduce some bias as there may be additional studies not included in this review. However, it is our aim to perform frequent updates as we expect an increase in research in this area in the coming years. </p> <p>In summary, there is some evidence that sulthiame is effective in controlling seizures in the short‐term in children with BECTS. However, the study had a small sample size which can affect precision of the results. Currently, use of sulthiame is uncommon in many parts of the world thus limiting its applicability. The trials which compared two AEDs did not inform us of which AED was superior as far as seizure remission in BECTS is concerned. There is still no evidence from the RCTs reviewed regarding whether choice of AED treatment in BECTS makes a difference to seizure remission in the medium or longer term. Regarding the area of cognitive effects, there is also insufficient evidence comparing those on different AED treatments and to date no RCTs have been performed comparing the effects of treatment with no treatment/placebo. </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD006779-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Sulthiame versus placebo (Rating 2000): Kaplan‐Meier plot of seizure free patients" data-id="CD006779-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Sulthiame versus placebo (<a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a>): Kaplan‐Meier plot of seizure free patients </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full#CD006779-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006779-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Clobazam versus Carbamazepine, Outcome 1 Proportion of patients who are seizure free from 4‐40 weeks." data-id="CD006779-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Clobazam versus Carbamazepine, Outcome 1 Proportion of patients who are seizure free from 4‐40 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006779-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Clobazam versus Carbamazepine, Outcome 2 Proportion of patients who had seizure remission in the last 9 months of the study." data-id="CD006779-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Clobazam versus Carbamazepine, Outcome 2 Proportion of patients who had seizure remission in the last 9 months of the study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006779-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Clobazam versus Carbamazepine, Outcome 3 Proportion of patients who discontinued due to adverse events." data-id="CD006779-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Clobazam versus Carbamazepine, Outcome 3 Proportion of patients who discontinued due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006779-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Clobazam versus Carbamazepine, Outcome 4 Proportion of patients who reported adverse events." data-id="CD006779-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Clobazam versus Carbamazepine, Outcome 4 Proportion of patients who reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006779-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Levetiracetam versus Oxcarbazepine, Outcome 1 Proportion of patients who are seizure free at 3 months." data-id="CD006779-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Levetiracetam versus Oxcarbazepine, Outcome 1 Proportion of patients who are seizure free at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006779-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Levetiracetam versus Oxcarbazepine, Outcome 2 Proportion of patients who are seizure free at 12 months." data-id="CD006779-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Levetiracetam versus Oxcarbazepine, Outcome 2 Proportion of patients who are seizure free at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006779-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Levetiracetam versus Oxcarbazepine, Outcome 3 Proportion of patients who discontinued treatment due to adverse events." data-id="CD006779-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Levetiracetam versus Oxcarbazepine, Outcome 3 Proportion of patients who discontinued treatment due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006779-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Levetiracetam versus Oxcarbazepine, Outcome 4 Proportion of patients who reported adverse events." data-id="CD006779-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Levetiracetam versus Oxcarbazepine, Outcome 4 Proportion of patients who reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006779-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Carbamazepine versus Topiramate, Outcome 1 Proportion of patients who are seizure free at 28 weeks." data-id="CD006779-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Carbamazepine versus Topiramate, Outcome 1 Proportion of patients who are seizure free at 28 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006779-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Carbamazepine versus Topiramate, Outcome 2 Proportion of patients who discontinued treatment due to adverse events." data-id="CD006779-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Carbamazepine versus Topiramate, Outcome 2 Proportion of patients who discontinued treatment due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006779-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Carbamazepine versus Topiramate, Outcome 3 Proportion of patients who have somnolence as adverse event." data-id="CD006779-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Carbamazepine versus Topiramate, Outcome 3 Proportion of patients who have somnolence as adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006779-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Carbamazepine versus Topiramate, Outcome 4 Proportion of patients who have rash as an adverse event." data-id="CD006779-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Carbamazepine versus Topiramate, Outcome 4 Proportion of patients who have rash as an adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006779-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Sulthiame versus placebo, Outcome 1 Proportion of patients who are seizure free at 3 months." data-id="CD006779-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Sulthiame versus placebo, Outcome 1 Proportion of patients who are seizure free at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006779-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Sulthiame versus placebo, Outcome 2 Proportion of patients who are seizure free at 6 months." data-id="CD006779-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Sulthiame versus placebo, Outcome 2 Proportion of patients who are seizure free at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006779-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Sulthiame versus placebo, Outcome 3 Proportion of patients who reported adverse events." data-id="CD006779-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Sulthiame versus placebo, Outcome 3 Proportion of patients who reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006779-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/urn:x-wiley:14651858:media:CD006779:CD006779-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_t/tCD006779-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Sulthiame versus placebo, Outcome 4 Time to first seizure after randomisation." data-id="CD006779-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Sulthiame versus placebo, Outcome 4 Time to first seizure after randomisation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/media/CDSR/CD006779/image_n/nCD006779-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006779-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Clobazam compared with Carbamazepine for patients with BECTS</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: Patients with a clinical and EEG diagnosis of BECTS</b> </p> <p><b>Settings: Single centre in Cuba</b> </p> <p><b>Intervention: Clobazam</b> </p> <p><b>Comparison: Carbamazepine</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk on Carbamazepine</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk on Clobazam</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who are seizure free between 4‐40 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 100<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 100<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> </p> <p>(0.67 ‐ 1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<sup>2</sup> </p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>3</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who had seizure remission in the last 9 months of the study</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 100<sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 100<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b> </p> <p>(0.84 ‐ 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>5</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion of patients who discontinued treatment due to adverse events</b> </p> <p><b>(96 weeks trial period)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 per 1000<sup>6</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>56 per 1000<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.72</b> (0.05, 10.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>7</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One patient on clobazam discontinued due to rash whilst one on carbamazepine discontinued due to somnolence. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who reported adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 100<sup>8</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 100<sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.92</b> </p> <p>(0.59 ‐ 6.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>7</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion of patients with a particular or serious adverse event:</b> </p> <p>1. Vertigo</p> <p>2. Headache</p> <p>3. Somnolence</p> <p>4. Nausea/Vomiting</p> <p>5. Tremor</p> <p>6. Fatigue</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>17 per 100<sup>9</sup> </p> <p>11 per 100<sup>9</sup> </p> <p>17 per 100<sup>9</sup> </p> <p>56 per 1000<sup>9</sup> </p> <p>17 per 100<sup>9</sup> </p> <p>17 per 100<sup>9</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 100<sup>9</sup> </p> <p>16 per 100<sup>9</sup> </p> <p>12 per 100<sup>9</sup> </p> <p>20 per 1000<sup>9</sup> </p> <p>4 per 100<sup>9</sup> </p> <p>8 per 100<sup>9</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>8</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The numbers in each group range from 1 to 5 patients. These are too small to compare if any statistical differences exist. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Changes in cognitive function testing from baseline (96 weeks trial period)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See<sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 baseline, 38 at end of trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<sup>8</sup> <br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; [other abbreviations, e.g. OR, etc] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The proportion of patients who were seizure free between 4 ‐ 40 weeks of the trial were 64% for those on carbamazepine and 66.7% for those on clobazam. We have rounded these off to 64 and 68 per 100 respectively. </p> <p><sup>2</sup> The study had 45 eligible participants but two were not randomised (no reasons given). </p> <p><sup>3</sup>The study was an open‐label study. There were inconsistencies in the reports regarding the numbers of excluded subjects e.g. in the carbamazepine group. </p> <p><sup>4</sup> The proportion of patients who had seizure remission during the last 9 months of the trial were 84% for those on carbamazepine and 88.9% for those on clobazam. We have rounded these off to 89 and 84 per 100 respectively. </p> <p><sup>5</sup> The study was an open‐label study. There were inconsistencies in the reports regarding the numbers of excluded subjects e.g. in the carbamazepine group. </p> <p><sup>6</sup> The proportion of patients who discontinued treatment due to adverse events was 4% for those in the carbamazepine group and 5.6% for those in the clobazam group. We have rounded these off to 40 and 56 per 1000 respectively. </p> <p><sup>7</sup> Reporting of adverse effects may have been affected as participants were not blinded. Elsewhere in the paper (footnotes of Table 1 in original paper), it was reported that five patients were excluded due to adverse events: three due to a severe rash, and two due to a combination of increasing seizures, the appearance of cognitive deficits, and reports from parents and teachers on a change in behaviour. It was not mentioned which arm of treatment these patients were randomised to, if this was done, and we were uncertain about whether they were considered to have dropped out. </p> <p><sup>8</sup> The proportion of patients who reported adverse events were 32% for those on carbamazepine and 16.7% for those on clobazam. We have rounded these off to 32 and 17 per 100 respectively. </p> <p><sup>9</sup> The proportion of patients reporting specific adverse events are listed under the subtitle Effects of Interventions in this review. </p> <p><sup>10</sup> The neuropsychometric evaluation explain how the patients were grouped into no, mild, moderate and severe learning difficulties. Four of 25 patients randomised to carbamazepine did not have baseline evaluations which could affect the estimates of the results. The results show that three patients of 18 in the clobazam and three of 21 in the carbamazepine groups had moderate to severe learning difficulties at baseline. At the end of the trial, no patients of 17 evaluated in the clobazam group and one of 21 in the carbamazepine group had moderate to severe learning difficulties. Unfortunately, this interesting report of an improvement in cognition did not benefit from adequate reporting and there were no mean cognitive scores provided. The cause of the apparent improvement was not corroborated with seizure remission. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full#CD006779-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006779-tbl-0002"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Levetiracetam compared with Oxcarbazepine for patients with BECTS</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: Patients between three and 12 years old with clinical and EEG diagnosis of BECTS</b> </p> <p><b>Settings: Epilepsy outpatient clinics from three tertiary centres in Italy</b> </p> <p><b>Intervention: Levetiracetam</b> </p> <p><b>Comparison: Oxcarbazepine</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Illustrative comparative risks (95% CI)</p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Risk on Oxcarbazepine</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Risk on Levetiracetam</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who are seizure free at 3 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 100<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>100 per 100<sup>1</sup> </p> <p>(83 ‐ 121)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> (0.93 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who are seizure free at 12 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 100<sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>86 per 100<sup>3</sup> </p> <p>(60 ‐ 111)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.29</b> (0.89 to 1.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who discontinued treatment due to adverse events</b> </p> <p><b>(mean follow‐up period of 18.5 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1,000<sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1,000<sup>4</sup> </p> <p>(3 ‐ 612)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> (0.06 to 12.75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion of patients with an adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11 per 100<sup>6</sup> </p> <p>(2 ‐ 46)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>14 per 100<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.78</b> </p> <p>(0.15 to 4.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Changes in cognitive function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The outcome was not measured in the study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The proportion of patients who remained seizure free at three months after randomisation was 89% for those on oxcarbazepine and 100% for those on levetiracetam. We have rounded these off to 89 and 100 per 100 respectively. </p> <p><sup>2</sup> The study was unblinded. The age at randomisation in the two intervention groups differed causing heterogeneity that would influence the reported results. The small sample size produced a wide confidence interval resulting in imprecision of the estimated effect. </p> <p><sup>3</sup> The proportion of patients who remained seizure free at three months after randomisation was 67% for those on oxcarbazepine and 86% for those on levetiracetam. We have rounded these off to 67 and 86 per 100 respectively. </p> <p><sup>4</sup> The proportion of patients who discontinued treatment due to adverse events were 5.6% for those on oxcarbazepine and 4.8% for those levetiracetam. We have rounded these off to 56 and 48 per 1,000 respectively. </p> <p><sup>5</sup> The study was unblinded and the duration when interventions were used were not fixed. This makes comparison of adverse events difficult. </p> <p><sup>6</sup> The proportion of patients who reported adverse events were 11.1% for those on oxcarbazepine and 14.3% for those on levetiracetam. We have rounded these off to 11 and 14 per 100 respectively. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full#CD006779-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006779-tbl-0003"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Carbamazepine compared with Topiramate for patients with BECTS</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: Patients between five and 15 years old with a diagnosis of BECTS</b> </p> <p><b>Settings: 12 centres in Korea</b> </p> <p><b>Intervention: Carbamazepine</b> </p> <p><b>Comparison: Topiramate</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Illustrative comparative risks (CI 95%)</p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Risk on Topiramate</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Risk on Carbamazepine</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who are seizure free at 28 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>69 per 100<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>70 per 100<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> (0.77 to 1.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who discontinued treatment due to adverse events</b> </p> <p><b>(28 weeks trial period)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>10 per 100<sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>9 per 100<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> (0.36 to 3.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion of patients with an adverse event:</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not reported in the study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients with a particular or serious adverse event:</b> </p> <p>1. Somnolence</p> <p>2. Rash</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>12 per 100<sup>5</sup> </p> <p>2 per 100<sup>5</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>9 per 100<sup>5</sup> </p> <p>15 per 100<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (0.4‐3.9)</p> <p>8.59 (1.1 ‐ 66.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112 (1 study)</p> <p>112 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Changes in cognitive function testing from baseline</b> </p> <p><b>(28 weeks trial period)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>low</b> </p> <p>⊕⊕⊝⊝<sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The pattern of neuropsychometric changes with topiramate seemed to be slightly worse than carbamazepine. When only those on minimum doses of both drugs were considered (n = 70), the scores for cognitive function were similar. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The proportion of patients who were seizure free at 28 weeks of the trial were 68.9% for those on topiramate and 70.3% for those on carbamazepine. We have rounded these off to 69 and 70 per 100 respectively. </p> <p><sup>2</sup>The study was observer‐blinded only. It had a large proportion of patients who were lost to follow‐up in whom the results were carried forward from the last observation. </p> <p><sup>3</sup> The proportion of patients who discontinued treatment due to adverse effects was 10.3% for those on topiramate and 9.3% for those on carbamazepine. We have rounded these off to 10 and 9 per 100 respectively. </p> <p><sup>4</sup> The study was observer blinded though, in this case, the incomplete outcome data does not affect the outcome. The wide confidence interval makes results imprecise. </p> <p><sup>5</sup> The proportion of patients who had somnolence as an adverse event was 12.1% for those on topiramate and 9.3% for those on carbamazepine. The proportion of patients who had rash as an adverse event was 1.7% for those on topiramate and 14.8% for those on carbamazepine. We have rounded these off to 12, 9, 2, and 15 per 100 respectively. </p> <p><sup>6</sup> Reporting of adverse effects may have been affected as participants were not blinded. Adverse events were not documented actively by caregivers </p> <p><sup>7</sup> There was a high loss to follow‐up which could affect the estimates of changes in cognitive function. Moreover, results were described according to the P value with no reports of the differences in mean change scores. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full#CD006779-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006779-tbl-0004"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sulthiame compared with placebo for patients with BECTS</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: Patients between three and 10 years old with a diagnosis of BECTS</b> </p> <p><b>Settings: 26 centres in Europe</b> </p> <p><b>Intervention: Sulthiame</b> </p> <p><b>Comparison: Placebo</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Illustrative comparative risks (95% CI)</p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Assumed risk</p> <p>(Placebo)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Corresponding risk</p> <p>(Sulthiame)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who are seizure free at 3 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 100<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>90 per 100<sup>1</sup> </p> <p>(59 ‐ 138)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.26</b> (1.48 to 3.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>2</sup> </p> <p><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who are seizure free at 6 months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 100<sup>2</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>68 per 100<sup>3</sup> </p> <p>(37 ‐ 126)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.63</b> (1.43 to 4.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>2</sup> </p> <p><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure after randomisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazard ratio 7.8 (2.66 to 22.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<sup>2</sup> </p> <p><b>moderate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of patients who discontinued treatment due to adverse events (over 6 months trial period)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 patients discontinued treatment due to adverse events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion of patients with an adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43 per 100<sup>4</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>58 per 100<sup>4</sup> </p> <p>(36 ‐ 95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.35</b> (0.83 to 2.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<sup>5</sup> </p> <p><b><sup>moderate</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Changes in cognitive function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 (1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This outcome was not measured in the study.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The proportion of patients who remained seizure free at three months after randomisation was 40% for those on placebo and 90% for those on sulthiame. We have rounded these off to 40 and 90 per 100 respectively. </p> <p><sup>2</sup> The quality of evidence was downgraded given the limitations in the study of the small sample size affecting precision of results. </p> <p><sup>3</sup> The proportion of patients who remained seizure free at six months after randomisation was 26% for those on placebo and 68% for those on sulthiame. We have rounded these off to 26 and 68 per 100 respectively. </p> <p><sup>4</sup> The proportion of patients who reported adverse events were 58.1% for those on sulthiame and 42.9% for those on placebo. We have rounded these off to 58 and 43 per 100 respectively. </p> <p><sup>5</sup> Adverse events were recorded during assessments and not actively by caregivers. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full#CD006779-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006779-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Participant characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant numbers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Male:Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*Age when seizures started (years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*Age when randomised (years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Frequency of seizures on randomisation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clobazam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12:6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not clearly stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.22 +/‐ 1.3 (7‐11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not given (6 or more per month)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbamazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10:15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not clearly stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4 +/‐ 1.3 (7‐10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not given (6 or more per month)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Levetiracetam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11:10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 1.8 per month</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10:8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 1.5 per month</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0003" title="KangH‐C , EunB‐L , LeeCW , MoonHK , KimJ‐S , KimDW , et al. A multicenter, randomized, open‐labeled, clinical study to evaluate the effect on cognitive and behavioral function of topiramate compared with carbamazepine as monotherapy in children with benign rolandic epilepsy. Epilepsia2006;47 Suppl 4:138. KangHC , EunBL , Wu LeeC , Ku MoonH , KimJS , Wook KimD , et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia2007;48(9):1716‐23. LimK , KimHD , Korean BRE Study Group. Low‐dose topiramate compared with carbamazepine in treating benign rolandic epilepsy. Epilepsia2004;45 Suppl 7:322‐3. ">Kang 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbamazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32:22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not given</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32:26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not given</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sulthiame</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16:15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6 (1.9 ‐10.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2 (3.9 – 10.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 3 (2 – 10) during 6‐months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24:11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7 (3 – 10.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4 (3.1 – 10.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median 2 (2 – 20) during 6‐months</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>* Mean age (except study by <a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a>, where median age reported) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Participant characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full#CD006779-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006779-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analysis</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outcome reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Best outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Best outcome RR (CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported</p> <p>outcome RR (CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worst outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worst outcome RR (CI)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seizure free at 4‐40 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clobazam</p> <p>Carbamazpine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/18 = 72%</p> <p>16/25 = 64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13</p> <p>(0.75 ‐ 1.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/18 = 66.7%</p> <p>16/25 = 64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04</p> <p>(0.67 ‐ 1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/18 = 66.7%</p> <p>18/25 = 72.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93</p> <p>(0.62 ‐ 1.39)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seizure remission in last 9 months of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clobazam</p> <p>Carbamazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/18=94.4%</p> <p>21/25 = 84%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12</p> <p>(0.92 ‐ 1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/18 = 88.9%</p> <p>21/25 = 84%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06</p> <p>(0.84, 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/18 = 88.9%</p> <p>22/25 = 88%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01</p> <p>(0.81 ‐ 1.26)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seizure remission at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Levetiracetam</p> <p>Oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/21 = 100%</p> <p>16/18 = 88.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13</p> <p>(0.93 ‐ 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/21 = 100%</p> <p>16/18 = 88.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13</p> <p>(0.93 ‐ 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/21 = 100%</p> <p>16/18 = 88.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13</p> <p>(0.93 ‐ 1.36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seizure remission at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Levetiracetam</p> <p>Oxcarbazepine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/21 = 90.5%</p> <p>12/18 = 66.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.36</p> <p>(0.95 ‐ 1.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/21=85.7%</p> <p>12/18 = 66.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29</p> <p>(0.89 ‐ 1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/21 = 85.7%</p> <p>13/18 = 72.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19<br/> (0.85 ‐ 1.66) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0003" title="KangH‐C , EunB‐L , LeeCW , MoonHK , KimJ‐S , KimDW , et al. A multicenter, randomized, open‐labeled, clinical study to evaluate the effect on cognitive and behavioral function of topiramate compared with carbamazepine as monotherapy in children with benign rolandic epilepsy. Epilepsia2006;47 Suppl 4:138. KangHC , EunBL , Wu LeeC , Ku MoonH , KimJS , Wook KimD , et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia2007;48(9):1716‐23. LimK , KimHD , Korean BRE Study Group. Low‐dose topiramate compared with carbamazepine in treating benign rolandic epilepsy. Epilepsia2004;45 Suppl 7:322‐3. ">Kang 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seizure remission at 28 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Carbamazepine</p> <p>Topiramate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38/54 = 70.3%</p> <p>27/58 = 46.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.51</p> <p>(1.09 ‐ 2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38/54 = 70.3%</p> <p>40/58 = 68.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.02</p> <p>(0.8 ‐ 1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/54 = 50%</p> <p>40/58 = 68.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72</p> <p>(0.53 ‐ 1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seizure remission at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sulthiame</p> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/31 = 93.5%</p> <p>14/35 = 40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.34</p> <p>(1.54 ‐ 3.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/31 = 90.3%</p> <p>14/35 = 40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.26</p> <p>(1.48 ‐ 3.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/31 = 90.3%</p> <p>16/35 = 45.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.98</p> <p>(1.35 ‐ 2.89)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seizure remission at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sulthiame</p> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/31 = 87.1%</p> <p>9/35 = 25.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.39</p> <p>(1.9 ‐ 6.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/31 = 67.7%</p> <p>9/35 = 25.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.63</p> <p>(1.43 ‐ 4.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/31 = 67.7%</p> <p>14/35 = 40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.69</p> <p>(1.06 ‐ 2.72)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>In the sensitivity analysis, "best outcome" imputes an outcome for missing data with replacement values favouring the intervention reported to have the higher relative risk of seizure remission, whilst "worst outcome" imputes values for missing data favouring the intervention reported to have the lower relative risk of seizure remission. The analysis shows that seizure remission was not influenced by the withdrawal of participants in the studies by <a href="./references#CD006779-bbs2-0001" title="AndradeR , Garcia‐EspinosaA , Machado‐RojasA , Garcia‐GonzalezME , Trapaga‐QuincosesO , Morales‐ChaconLM . A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of rolandic epilepsy. [Estudio prospectivo, abierto, controlado y aleatorizado de clobazam frente a carbamacepina en pacientes con crisis frecuentes de epilepsia rolandica.]. Revista de Neurologia2009;49(11):581‐6. ">Andrade 2009</a>, <a href="./references#CD006779-bbs2-0002" title="CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open‐label, parallel group trial. Brain and Development2007;29:281‐4. CoppolaG , FranzoniE , VerrottiA , GaraneC , SarajlijaJ , OpertoF , et al. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign rolandic seizures in children: an open‐label, parallel group study. Epilepsia2006;47 Suppl 3:179‐80. ">Coppola 2007</a> and <a href="./references#CD006779-bbs2-0004" title="RatingD , WolfC , BastT . Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6‐month randomized, double‐blind, placebo‐controlled study. Epilepsia2000;41(10):1284‐8. ">Rating 2000</a>. This was because the numbers were small and were balanced between the groups. In <a href="./references#CD006779-bbs2-0003" title="KangH‐C , EunB‐L , LeeCW , MoonHK , KimJ‐S , KimDW , et al. A multicenter, randomized, open‐labeled, clinical study to evaluate the effect on cognitive and behavioral function of topiramate compared with carbamazepine as monotherapy in children with benign rolandic epilepsy. Epilepsia2006;47 Suppl 4:138. KangHC , EunBL , Wu LeeC , Ku MoonH , KimJS , Wook KimD , et al. The effects on cognitive function and behavioural problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia2007;48(9):1716‐23. LimK , KimHD , Korean BRE Study Group. Low‐dose topiramate compared with carbamazepine in treating benign rolandic epilepsy. Epilepsia2004;45 Suppl 7:322‐3. ">Kang 2007</a>, the excessive drop‐out rate in this study could affect the estimate of seizure remission in the topiramate and carbamazepine groups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/full#CD006779-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006779-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Clobazam versus Carbamazepine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Proportion of patients who are seizure free from 4‐40 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.67, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion of patients who had seizure remission in the last 9 months of the study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.84, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proportion of patients who discontinued due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.05, 10.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Proportion of patients who reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [0.59, 6.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Clobazam versus Carbamazepine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006779-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Levetiracetam versus Oxcarbazepine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Proportion of patients who are seizure free at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.93, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion of patients who are seizure free at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.89, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proportion of patients who discontinued treatment due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.06, 12.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Proportion of patients who reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.24, 6.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Levetiracetam versus Oxcarbazepine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006779-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Carbamazepine versus Topiramate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Proportion of patients who are seizure free at 28 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.80, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion of patients who discontinued treatment due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.29, 2.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proportion of patients who have somnolence as adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.44, 3.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Proportion of patients who have rash as an adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.59 [1.11, 66.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Carbamazepine versus Topiramate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006779-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sulthiame versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Proportion of patients who are seizure free at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [1.48, 3.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion of patients who are seizure free at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.63 [1.43, 4.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proportion of patients who reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.83, 2.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Time to first seizure after randomisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.80 [2.66, 22.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sulthiame versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006779.pub2/references#CD006779-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006779.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006779-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006779-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006779-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD006779-note-0001">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006779\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006779\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006779\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006779\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006779\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006779\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006779\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006779\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006779\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006779\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006779\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006779\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006779\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006779\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006779\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006779\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006779\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006779\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UiM8QuvV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006779.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006779.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006779.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006779.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006779.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718922801"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006779.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718922805"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006779.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ddc29c97e1be5',t:'MTc0MDcxODkyMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 